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What’s already known about this topic?   
Cutaneous adnexal carcinomas are rare tumors, but their incidence is increasing. Their rarity prevents 
from gaining sufficient clinico-pathological experience: CACs can be a diagnostic challenge due to 
mostly non-specific clinical presentation and histopathological variety that often requires specific 
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What does this study add?   
CAC incidence increased from 2.5in 1985-87 to 19per million person-years in 2009-10; from 1997 it 
constantly increased rising up to 159% in 2010.  In patients with cutaneous adnexal carcinoma, the 
risk of SCC is 34-times higher than in general population.  Considering demographic evolution with 
progressive population’s ageing and higher CACs’ incidence among elderly, it is reasonable to expect 
a further increase in the future.  
 
Abstract 
Background: Recent studies have shown an increasing incidence of cutaneous adnexal carcinomas 
(CACs) over the years. 
 
Objective: The aim of our study was to evaluate incidence and survival of CACsand investigate their 
association with other skin neoplasms. 
 
Methods: Population based study. Data on incident cases of CACs were obtained from the Tuscany 
Cancer Registry (TCR) between 1985 and 2010. In order to determine if the occurence of squamous 
cell carcinoma (SCC) among patients with CAC is higher or lower than expected in the general 
population, standardized incidence ratio (SIR) was calculated. 
 
Results: 242 patients with CAC were observed; age–standardized incidence rate was 3.8 cases per 
millionperson-years. From 1997 to 2010, crude-incidence rates increased by 159%. Age-specific 
incidence was higher in males over 80 year-oldthan females of the same age and younger individuals. 
Carcinomas of sweat gland originprevailed; the most common histotype was porocarcinoma and the 
most frequentlyaffected site was the head-neck. 88% of CACs was diagnosed at a localized stage. 5-
year overall survival and disease-specific survival rates were 59% (95%CI 53-65) and 94% (95%CI 
91-98), respectively. In observation cohort, number of SCC was significantly higher than expected as 
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Conclusion: Increasing incidence warrants awareness and early diagnosis of cutaneous adnexal 
carcinomas. Increased SCC incidence among patients with these tumors highlights relevance of 
careful skin examination and follow-up. 
 
INTRODUCTION 
Cutaneous adnexal carcinomas (CACs) are a wide and heterogeneous group of malignant skin 
neoplasms that differentiate towards one or more appendageal structures: apocrine and eccrine sweat 
glands, hair follicle and sebaceous gland.1 Classification is based on apocrine-eccrine, follicular or 
sebaceous differentiation displayed on histopathological examination. CACs most often present as 
single nodules or asymmetric plaques, sometimes ulcerated, with variable growth-rate, lacking in 
distinctive dermoscopical features. 2-5 They are rare tumors with age-standardized incidence rateof 5.1 
per million person-years in the USA and 2.8 in Europe (5.3 in the Netherlands).6-9 In Italy crude-
incidence rate is 6.1 per million (1343 cases observed in 2000-10) with 424 new cases diagnosed in 
2015 (3.4% of all skin tumors registered in the same period).5Theirrarity prevents from gaining 
sufficient clinico-pathological experience and definite diagnosis oftenrequires specific expertise.10,11 
However incidence of these tumors has increased in recent years both in the USA and in Europe.6,7,12 
Remarkably theincidence temporal trend has been similar to that of basal cell carcinoma (BCC), 
squamous cell carcinoma (SCC), and melanoma.6 Complete surgical excision is the treatment of 
choice; treatment of metastatic disease is described only in case-reports and there is no consensus 
about the most suitabletherapeutic regimen being CACs often poor responsive to traditional 
chemotherapy.13 The role of target therapy is under investigation.14Adjuvant radiotherapy may play a 
role for regional or distant disease control.15 Therefore prognosis is generally good when the neoplasm 
is localized to the skin, but deteriorates when distant organs are involved.7,16,17 
 
The present study examined a 25-years time period (1985-2010) in order to evaluate the burden of 
CACs in terms of incidence and survival. Based on Tuscany Cancer Registry (TCR) reports, we 
evidenced the registration of multiple skin cancers in several patients with CAC. Since all occurred 
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yet, we decided to investigate the association between CAC and SCC.  In order to determine if the 
incidence of SCC among patients with CAC is higher or lower than expected, given the general 
population and age distribution, standardized incidence ratio (SIR) was calculated. 
 
MATERIALS AND METHODS 
We obtained and reviewed all cases of CACscollected from January 1st 1985 to December 31st 2010 
by the Tuscany Cancer Registry (TCR), a population-based cancer registry active in the Italian area of 
Florence and Prato(inhabitants 1.2 million, area 3879 square kilometers). The source population was 
30.720.481 individuals. One participant could contribute with several CACs. Cases were followed-up 
until December 1st 2016 considering the date of death or the date of last access to regional health 
services for any reason.Registry structure and methods have been previously reported.18 The 
following morphological codes, according to World Health Organization’s International Classification 
of Diseases for Oncology Third Edition (ICD-O-3), were considered: 8102/3, 8110/3, 8200/3, 8211/3, 
8400-03/3, 8407-10/3, 8413/3, 8420/3, 8480-81/3, 8940/3.19Cases with topographic code C44 (skin) 
were included. Paget's disease was excluded for non-homogeneous coding. The variables considered 
for each patient were gender, age, tumor stage, anatomical localization, treatment, metastasis, and 
other neoplasms. All data were de-identified and tracked using a registry code number.  According to 
Surveillance, Epidemiology and End Results Program Registries (SEER) summary staging system, 
tumor stage was classified in localized, regional, and distant.20In situ tumors were also considered.  
 
Statistical analysis 
Incidence rates were expressed per 1 million person-years and age-adjusted to the European Standard 
Population using the direct method.21,22Age-specific incidence rates and incidence rate ratios (IRR) 
were calculated. Age-standardized incidence rate (ASR) confidence interval (CI) was calculated using 
binomial approximation. The survival end points were 5-year overall survival (OS) and 5-year 
disease-specific survival (DSS) rates; these were calculated using the life-table method.23 OS defines 
the time from CAC’s diagnosis to death from any cause or last follow-up; DSS the time from 
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ends that the patient survives without any signs or symptoms of that cancer.Disease-specific survival 
rates at 1 and 5 years indicate the proportion of patients who have not die due to CAC at 1 and 5 years 
from the date of diagnosis of the neoplasm; patients who died from other causes were censored. 
In order to investigate if the occurence of SCC among patients with CAC was higher or lower than 
expected, standardized incidence ratio (SIR) was calculated. SIR is defined as the ratio between the 
number of SCC observed in patients with CAC and the number of SCCexpected inthe observation 
period (1985-2010)based on general population age-specific incidence rates. Only first SCCs were 
included in calculating the SIR.Statistical analysis was performed using Stata software version 11 




242 CACs were registered, 132 (55%) males and 110 (45%) females (Table I). ASR was 3.8 per 
million person-years(95%CI 3.2-5.2) and 7.8 was the crude incidence rate. Incidence increased from 
2.5 in 1985-87 to 19 in 2009-10; from 1997 it constantly increased rising up to 159% in 2010 (Figure 
1). Age-specific incidence rates remarkably rose from 0.9 in people ageing 30-34 years to 118 in 
those aged 85 or older (Figure 2). The incidence was higher in males (8.9) than females (6.8) with an 
IRR of 1.3. No cases were found inunder25.No patients had multiple CACs. 
 
Carcinomas with sweat gland differentiation prevailed (198 cases,82%), followed by carcinomas with 
sebaceous differentiation (32 cases,13%).Porocarcinoma represented the most common histotype 
(55%, Table II) and the most frequent entity among both males and females (50.8% and 60% of CACs 
diagnosed respectively). Other recorded histotypes were: sebaceous carcinoma (13%), 
hidradenocarcinoma (12%), apocrine carcinoma (5%), adenoid cystic carcinoma, microcystic adnexal 
carcinoma and adnexal carcinoma with follicular differentiation (3.7% each), eccrine carcinoma (2%), 
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Age at diagnosis ranged from 26 to 99 years and mean age was 76.5 (SD = 14.1), 81 considering 
porocarcinoma. 
 
56% of CACs was localized on the head-neck region, especially the face, including eyelid, lip, and ear 
(Figure 3). In males most neoplasms presented on scalp (23% vs 10% in females), whereas in females 
on lower limbs (16% vs 8% in males) and on trunk (21% vs 14% in males, Table I). Considering all 
histotypes the most common site was the head-neck (Table II), except from apocrine carcinoma that 
in 5 out of 12 cases was localized on trunk, preferentially in axillary region (Figure 3).By all 
anatomical sites the most common histotype was porocarcinoma: it represented almost half of 
carcinomas arising on face (47%) and trunk (49%), 63% of those arising on scalp, and more than 80% 
of CACs on extremities (Table II). 
 
88% of CACs was localized to the skin at diagnosis while 4.5% extended directly into surrounding 
tissues and/or involved regional lymph nodes (Table I). Only 2.5% was diagnosed at distant stage. In 
situ tumors represented 3.7% and they were all intraepidermal porocarcinomas (Table II).  
 
During follow-up period (mean follow-up time 85 months), 11 CACs (5 localized and 6 regional) 
metastasized. Taking into account all CACs that metastasized during follow-up, DFS was 70.6 
months (median 25). Regional stage carcinomas had 32 months DFS (median 22).  
 
Metastases were more commonly observed in males (Table I), mainly due to CACs primitively 
located on head-neck (9/17) and with sweat gland differentiation, particularly porocarcinoma (Table 
II). Lung  (7/17), skin (4/17), brain (3/17), and liver (2/17) where more commonly involved. 
3 porocarcinomas and 1 sebaceous carcinoma of the upper eyelid (that invaded orbital structures), 
treated by radical surgical excision with negative margins, relapsed after 48.7 months (median 43.5). 
 
Surgery was performed in 99% of patients. In selected cases adjuvant chemotherapy and/or 
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5-year OS and DSS rate were 59% (95%CI 53-65) and 94% (95%CI 91-98), as shown in Figure 4. 
The median DSS was 27 months.  
 
123 (50.8%) patientspresented one or more other malignant tumor in their medical history: 61 patients 
had or had had an extracutaneous tumor, 96 a further skin cancer (including BCC, SCC, melanoma, 
Bowen disease, actinic keratosis, and Merkel cell carcinoma). 
 
During observation period (TCR, 1985-2010), 36 (14.9%) patientspresented at least one SCC, while 
1.07 cases of SCC would beexpected in the present cohort based on age-specific incidence rates. SIR 
resulted 33.71, p-value <0.0001 (i.e. observed SCCs were 33.71 times higher than expected). The 
histotypes of CACs associated with SCC are described in Table III. Taking into consideration SCC 
observed in patients with porocarcinoma, the two neoplasms arose on same anatomical region in 76% 
of cases, particularly on head region. Similar anatomical site concordance was equally observed in 
patients with other histological types.In 1/3 of cases SCC was diagnosed before CAC, in 1/3 at the 




Even in the Italian area of Florence and Prato (TCR, 1985-2010), CACs are rare tumors as ASR is 3.8 
per million person-years, which is higherthan ASR reported in Southern Europe (2.5) but overlaps 
with that registered in Northern Europe(p <0.01). 6,7,8Crude-incidence is 7.8although it resulted 12.6 in 
2000-10 twice the rate (6.1) described by Italian cancer report.9 Crude-incidence has increased over 
the years and fewer cases in1994-96 arelikely to be attributed to lower registration or coding system 
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Different factors may justify increasing temporal trend as real increase of incident cases,but also 
diagnostic techniques’ improvement via histopathological confirmation of all excised skin lesions, 
demographic evolution with population ageing (age-specific incidence peaks over 85 year-old) and 
finally greater awareness to skin cancer registration in recent decades. In support of real incidence 
boost of these tumors rather than improved diagnostic ability, Blake et al. demonstrated that such an 
increase applies to all tumor stages.6 In addition since their incidence trend is comparable to that 
reported for BCC, SCC, and melanoma it has been hypothetized that UV radiation may be implicated 
in CACs pathogenesis.6,7,24,25,26 
 
The excellent 5-year DSS (94%)can be explained by diagnosis of CACs predominantly at 
localized stage and efficacy of excisional surgery. It is higher than 5-year OS (59%) because more 
than half ofCACs are found in people over 80 year-old who died for other causes not related to CAC. 
In general our survival rates are lower than those reported in the USA.16 This discrepancy may be due 
toolder population (73% over 70 year-old in present studyvs 49% in Martinez et al.) and delayed 
diagnosis(2.5% distant stage vs 1.7%). It is worth mentioning that our study populationdiffers 
onsample size being that of Martinez et al. considerably bigger, nevertheless older age is a known 
cancer risk factor and elderly people have worse prognosis than younger ones. In fact DNA damage 
accumulates over time, resulting in malignant cellular transformation and immunosenescence that 
determines deficit of adaptive immunity and a protumorigenic inflammatory 
microenvironment.27Evenfibroblasts’ ability to scavenger oxygen free radicals is reduced in older skin 
with less protection against oxidative stress.28Diagnostic delay may also impact on survival, especially 
in elderly population where slow-growing skin lesions are often underestimated. 
 
CACs’ clinical presentation is heterogeneous, thus histopathological examination is 
mandatory representing the diagnostic gold standard. Incisional biopsy may not be representative of 
the tumor in its entirety, so an excisional biopsyis preferable. In the suspect of an adnexal carcinoma, 
it is necessary to avoid inappropriate destructivetreatments,as there is risk of recurrence and 
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invasion, status of deep and lateral excision margins.Classification of CACs poses many difficulties 
considering synonyms and dignity of definition of some entities.29-31 In our study carcinomas with 
sweat gland differentiationare the most common category (82%), followed by tumors with sebaceous 
differentiation(Table II) according to previous epidemiological studies. 6,7,9 Among tumors with sweat 
gland differentiation, the most frequent histotype is porocarcinoma representing 55% of all CACs, far 
above 7% reported by SEER Registries.6Porocarcinoma is also more common than sebaceous 
carcinoma that is the most frequent CAC diagnosed in both Dutch and American populations (13% vs 
25% and 35% respectively).6,7Since etiology of CACs remains still unknown, the comparison of 
different epidemiological patterns for specific histological types can provide useful insights.6 
Different histotype distribution may depend on selection and diverse composition of observed 
population as a result of exposure to different risk factors both environmental (geographic area, 
exposure to solar UV radiation, atmospheric pollution) and individual (concomitant diseases, 
immunosuppression, viral infections).32-36 
 
 The most frequent localization in sun-exposed areas (head-neck region with predominant 
onset on male scalp) as happensinNMSC,suggests a possible common etiopathogenesis represented 
by chronic sun-exposure.6,7,37 
 
An interesting result is that in the examined population we found a higher number of SCCs 
than expected based on age specific population incidence rates with a SIR of 33.7. It means 
thatpatients with CAC have a risk of developing an SCC 34-times higher than general 
population.Surprisingly,SCC were localized in the same anatomic region of CAC, particularlythe 
head (Table III). To date only a few case reports have described the association of CAC and SCC in 
the same patient and in only one case, an 86-year-old patient history of cumulative solarUV-exposure 
has been documented.38,39Cases in association with Bowen's disease or arising in the site of a previous 
Bowen have also been reported;40-42this finding, difficult to explain, may be due to the close histologic 
resemblance between Bowen’s disease and in situ porocarcinoma. Concomitant onset of CAC and 
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CAC arises, emphasizes the concept of field cancerization.43,44Strong site coincidence could be related 
to exposure to common risk factorssuch as solar UV radiation or other factors (i.e. genetic) not yet 
known. Recently,mutations compatible with sun radiation damage (UV mutational signature) and 
similar to those found in melanoma of the skin, SCC, and Merkel polyomavirus-negative cell 
carcinoma have been identified in porocarcinomas of the head.37,45In the present study, surveillance 
bias could also represent part of the explanation for the similar anatomical localizations of CAC and 
SCC. However, the TCR does not collect information about neither initial nor follow-up visits, so it is 
not known how much closely or with what frequencypatients have been followed-up or how much 
carefuleness was put in the medical examination. Being male and elder represents risk factor for both 
CAC and SCC: this is important in guiding dermatologists in clinically approaching these patients at 
initial visit and follow-up. 
 
To date for patients with CAC neither modality nor duration of follow-up has been 
established; on the basis of our results we propose to investigate patients as described in Figure 5. 
During follow-up other skin lesions eventually associated should be checked, especially considering 
SCC higher incidence in patients with CAC. Attention should be drawn to elderly male patients with 
porocarcinoma arising on head and patients with regional tumor stage at diagnosis. Disease-specific 
deaths’ concentration in the first 3 years from diagnosis (median DSS 27 months) highlights the 
opportunity of a close follow-up. It would be wise to prolong follow-up until 5 years from diagnosis 
given that recurrences observed occurred after 48.7 months. In patients with regional stage tumor 
attention should be kept in the first 2 years of follow-up, as median DFS was 22 months in this group. 
However, these considerations should be evaluated in the light of two main limits: relatively small 
sample size, which determines a strong statistical oscillation and influence of competitive mortality 
for other causes.  
It would be desirable to create a global register of rare skin cancersin order to allow a precise 
knowledge of the burden of CACs worldwide,47,48and include a section dedicated to these tumors in 
the guidelines of leading dermatology societies so to achieve uniform treatment and management, 
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CONCLUSION 
Considering demographic evolution with progressive population’sageing and higher CACs’incidence 
among elderly, it is reasonable to expect a further increase in the future. Therefore early diagnosis and 
propertreatment is crucial. Do never underestimate new onset of skin lesions in sun-exposed areas in 
elderly, especially in those who have history of adnexal carcinoma. 
 
Abbreviations 
ASR age-standardized incidence rate 
CAC cutaneous adnexal carcinoma 
CI confidence interval 
DFS disease-free survival 
DSS disease-specific survival 
IRR incidence rate ratio 
NMSC non melanoma skin cancer 
OS overall survival 
SCC squamous cell carcinoma 
SD standard deviation 
SIR standardized incidence ratio 
TCR Tuscany Cancer Registry 
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Figure legend 
Figure 1. “Trends in crude-incidence rates of cutaneous adnexal carcinomas in Tuscany Cancer 
Registry, 1985-2010.” 
Figure 2.  “Age-specific incidence curves for cutaneous adnexal carcinomas in males, females and 
both genders in Tuscany Cancer Registry, 1985-2010.” 
Figure 3.  “Anatomic location by gender and histotype of cutaneous adnexal carcinomas in Tuscany 
Cancer Registry, 1985-2010.” 
Figure 4.  “Overall survival and disease-specific survival rates among patients with cutaneous adnexal 
carcinoma in Tuscany Cancer Registry, 1985-2010.” 
Figure 5. “ ollow-up scheme based on TCR analysis, 1985-2010. Patients with CAC should be 
followed up every 6 months in the first 2 years and every year up to 5 years after initial diagnosis. 
Follow-up should include: complete history account, status andskin examination with palpation of 
main lymph node stations; ultrasonography of loco-regional draining lymph nodes and instrumental 
investigation of most common metastatic sites (i.e. lung, chest x-ray at diagnosis and the following 
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Table legend 
Table I. “ eatures of cutaneous adnexal carcinomas in Tuscany Cancer Registry, 1985-2010” 
Table II. “Cutaneous adnexal carcinomas according to histological type: cases distribution by gender, 
anatomical localization, tumor stage at diagnosis and metastases (TCR, 1985-2010).” 
Table III. “Association between cutaneous adnexal carcinoma and squamous cell carcinoma in 
Tuscany Cancer Registry, 1985-2010: SCC cases observed by CAC histological type, temporal 
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Table I. “ eatures of cutaneous adnexal carcinomas in Tuscany Cancer Registry, 1985-2010” 
 
 Gender 






Year of diagnosis 
1985-1990 27 (11) 17 (13) 10 (9) 
1991-1995 27 (11) 19 (14) 8 (7) 
1996-2000 31 (13) 15 (11) 16 (15) 
2001-2005 63 (26) 27 (20) 36 (33) 
2006-2010 94 (39) 54 (41) 40 (36) 
All years 242 (100) 132 (100) 110 (100) 
Age at diagnosis 
<55 20 (8) 7 (5) 13 (12) 
55-69 39 (16) 26 (20) 13 (12) 
70-84 94 (39) 57 (43) 37 (34) 
>85 89 (37) 42 (32) 47 (43) 
Primary site (topographical code ICD-O-3) 
Lip (C440) 3 (1) 2 (2) 1 (1) 
Eyelid (C441) 12 (5) 7 (5) 5 (5) 
Ear (C442) 15 (6) 12 (9) 3 (3) 
Head and neck (C443-4) 105 (43) 59 (45) 46 (42) 
Trunk (C445) 41 (17) 18 (14) 23 (21) 
Upper limb (C446) 18 (7) 11 (8) 7 (6) 
Lower limb (C447) 28 (12) 10 (8) 18 (16) 
Overlapping (C448) 2 (1) 1 (1) 1 (1) 
Unknown (C449) 18 (7) 12 (9) 6 (5) 
Stage 
In situ 9 (4) 5 (4) 4 (4) 
Localized 214 (88) 118 (89) 96 (87) 
Regional 11 (4) 3 (2) 8 (7) 
Distant 6 (2) 5 (4) 1 (1) 
Unknown 2 (1) 1 (1) 1 (1) 
Treatment 
Surgery 230 (95) 126 (95) 104 (95) 
Surgery + chemotherapy  4 (2) 2 (2) 2 (2) 
Surgery + radiotherapy 4 (2) 2 (2) 2 (2) 
Surgery + chemotherapy + radiotherapy 1 (0) 0 (0) 1 (1) 
Radiotherapy 1 (0) 1 (1) 0 (0) 
No treatment 2 (1) 1 (1) 1 (1) 
 
Metastasis* 17 (7) 10 (8) 7 (6) 
 
Lymph node dissection* 14 (6) 3 (2) 11 (10) 
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Table II. “Cutaneous adnexal carcinomas distribution according to histological type: cases distribution 


































































































133 67 66 44 26 20 
38 
(15;23) 
5 9 114 7 2 1 8 
Sebaceous carcinoma 
(8410/3) 
32 20 12 17 3 3 1 (1;0) 
8 0 31 0 0 1 0 
Hidradenocarcinoma 
(8400/3, 8402/3) 
29 16 13 12 4 8 5 (1;4) 
0 0 26 2 1 0 3 
Apocrine carcinoma 
(8401/3) 
12 6 6 3 1 5 1 (0;1) 




9 5 4 5 0 3 0 




9 6 3 4 3 2 0 
0 0 9 0 0 0 0 
CAC with follicular 
differentiation 
(8102/3, 8110/3) 
9 7 2 5 1 0 1 (1;0) 
2 0 9 0 0 0 0 
Eccrine carcinoma 
(8413/3) 
5 3 2 3 2 0 0 
0 0 4 0 1 0 1 
CAC NOS 
(8390/3) 
3 1 2 1 1 0 0 
1 0 3 0 0 0 0 
Mucinous carcinoma 
(8480/3) 
1 1 0 0 0 0 0 
1 0 1 0 0 0 0 
Total (all histological 
types) 
242 132 110 94 41 41 
46 
(18;28) 
20 9 214 11 6 2 17 
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Table III. “Association between cutaneous adnexal carcinoma and squamous cell carcinomain 
Tuscany Cancer Registry, 1985-2010: SCC cases observed by CAC histological type, temporal 




SCC diagnosis (compared to CAC) 
SCC and CAC site 
match(SCC observed per 
site) 
Earlier Concomitant Later All sites Head Limbs 
Porocarcinoma 21 (15;6) 8 8 5 16(19*) 15(16) 1(3) 
Hidradenocarcinoma 7 (6;1) 1 2 4 6(7) 6(7) 0(0) 
Sebaceous carcinoma 6 (4;2) 2 1 3 3(6) 2(4) 1(2) 
CAC with follicular 
differentiation 
1 (1;0) 1 0 0 1(1) 1(1) 0(0) 
Microcystic adnexal 
carcinoma 
1 (1;0) 1 0 0 1(1) 1(1) 0(0) 
All histological types 36 (27;9) 13 11 12 27(34*) 25(29) 2(5) 
SCC, squamous cell carcinoma; CAC, cutaneous adnexal carcinoma 
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